
Qiagen NV
QGEN · NYSE · Healthcare / Diagnostics & Research
Price History
Full chartMarket Stats
About
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Company Details
- SectorHealthcare
- IndustryDiagnostics & Research
- CEOMr. Jonathan M. Pratt
- Employees5.50K
- HeadquartersHulsterweg 82, Venlo, Netherlands, 5912 PL, USA
- Websitehttps://www.qiagen.com
Leadership
- Dr. Roland SackersCFO, MD & Member of Management Board · b. 1968
- Mr. Thierry L. BernardMember of Management Board · b. 1964
- Mr. Jonathan M. PrattCEO & Member of Management Board · b. 1970
- Mr. Antonio SantosSenior VP & Head of Global Operations
- Mr. Daniel Wendorff CEFA, CIIAVP & Head of Investor Relations
- Mr. John GilardiVP & Head of Corporate Communications
- Ms. Stephany FosterSenior VP & Head of Human Resources · b. 1979
- Dr. Thomas SchweinsSenior Vice President of Life Science Business Area
- Dr. Thomas TheuringerSenior Director & Head of External Communications
- Mr. Jean-Pascal ViolaSenior VP & Head of Corporate Strategy and Business Development
Financials
Income Statement
Balance Sheet
Cash Flow
Earnings
Key Statistics & Ratios
Analyst Ratings
- Strong Buy6
- Buy3
- Hold7
Ownership Breakdown
- Institutions
- 79.16%
- Insiders
- 0.48%
- Retail / Other
- 20.36%
Top Institutional Holders
- Wellington Management Company LLP12.41M6.01%
- T. Rowe Price Associates, Inc.8.43M4.08%
- Principal Financial Group Inc6.65M3.22%
- Vanguard Capital Management, LLC6.11M2.96%
- Deutsche Bank AG5.60M2.71%
- BlackRock Inc5.25M2.54%
- Amundi4.76M2.30%
- NORGES BANK4.33M2.09%
- Morgan Stanley - Brokerage Accounts4.19M2.03%
- Earnest Partners LLC3.87M1.87%
- Millennium Management LLC3.85M1.86%
- Bank of America Corp3.25M1.57%
- Helikon Investments Ltd3.09M1.49%
- Dimensional Fund Advisors, Inc.2.76M1.33%
- Fivespan Partners, LP2.69M1.30%
Top Fund Holders
- Vanguard Health Care Inv6.51M3.15%
- MFS International Equity R64.09M1.98%
- T. Rowe Price International Stock3.85M1.86%
- Vanguard Total Intl Stock Index Inv3.05M1.48%
- MFS Research International I2.53M1.22%
Dividends
Stock Splits
- Jan 25, 2017962:1000
- Jul 14, 20004:1
- Jul 16, 19992:1